Depending on the patient’s needs, we offer a range of specialised catheter lock solutions. TauroLock™-Hep100 is the right option for those who have previously benefited from heparin as an anti-occlusive agent.
Indication and Effect
TauroLock™-Hep100 has been approved for instillation in all central-venous access systems. This lock solution prevents the formation of a bacterial biofilm and thereby protects patients from catheter-related infections. At the same time, it ensures a high patency rate. We recommend TauroLock™-HEP100 for CVCs in oncology and parenteral nutrition.
TauroLock™-Hep100 contains three active ingredients:
- heparin (100 units per ml)
- citrate (4 %)
Taurolidine has a broad antimicrobial activity (incl. MRSA and VRE) against gram-positive and gram-negative bacteria and fungi (e.g. Candida). Heparin and citrate both help to prevent occlusions within the catheter.
In-between treatment sessions, TauroLock™-Hep100 is instilled into the saline-flushed access system. Please note that medical staff must check the filling volume of the respective catheter or port system.
Patients diagnosed with HIT should not use TauroLock™-Hep100 for their vascular access system (VAD). Instead, we recommend TauroLock™ and/ or TauroLock™-U25.000. Furthermore, TauroLock™ is not suitable if:
- patients have displayed a hypersensitive reaction to citrate or taurolidine
- patients are taking medication which interferes with either citrate, heparin, or taurolidine.
TauroLockTM-HEP100 must be aspirated before the next treatment.
Our customers may obtain TauroLock™-Hep100 in ampoules of 3 ml (single dose, 10 ampoules per box).
Storage & Transport
TauroLock™-Hep100 must be stored at 15 °C to 30 °C. Please note that you must not freeze TauroLock™-Hep100 under any circumstances.
For national guideline recommendations, e.g. GPOH 2018:
“Lock solutions containing taurolidine are recommended for the prevention of CVAD-associated infections.”
21.4 Taurolidine for the Prophylaxis against CVAD-related Infection
Lock solutions containing Taurolidine are recommended for the prevention of CVAD-associated Infections (scientific evidence Cat. IB, problem: reimbursement in outpatient care).
Taurolidine containing lock solutions are also recommended for paediatric-oncologic patients on cyclized (home-)parenteral nutrition if an infusion-free interval of at least 4 hours is available (Cat. IB for patients on home-parenteral nutrition).
23.6.3 Taurolidine-Lock for adjuvant therapy
Taurolidine (e.g. 1.35% Taurolidine, 4% Citrate) can be used as adjuvant measure during systemic treatment with antibiotics (Cat. II). The minimal dwell time in the catheter lumen is 4 hours.